Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2009-02-01 (17 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINT-MAUR-DES-FOSSES (94210), Val-de-Marne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
NATASCHA PHARMA : revenue, balance sheet and financial ratios
NATASCHA PHARMA is a French company
founded 17 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-MAUR-DES-FOSSES (94210),
this company of category PME
shows in 2025 a net income positive of 30 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - NATASCHA PHARMA (SIREN 510288699)
Indicator
2025
2024
2023
2021
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
29 505 €
10 729 €
41 642 €
-5 424 €
45 101 €
51 583 €
40 016 €
50 256 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, NATASCHA PHARMA generates positive net income of 30 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 50 k€ -> 30 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
29 505 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 112%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 39%. The balance between equity and debt is satisfactory.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
112.037%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
39.002%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2021
2023
2024
2025
Debt ratio
439.299
330.597
247.488
197.841
285.359
154.412
135.368
112.037
Financial autonomy
16.321
20.548
25.761
29.212
21.879
32.948
34.393
39.002
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
112.042025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Average
In 2025, the debt ratio of NATASCHA PHARMA (112.04) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
39.0%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Average
In 2025, the financial autonomy of NATASCHA PHARMA (39.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 156.16. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
156.155
Liquidity indicators evolution NATASCHA PHARMA
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2021
2023
2024
2025
Liquidity ratio
126.901
148.608
126.977
140.737
147.507
180.69
154.517
156.155
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
156.162025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Average-8 pts over 3 years
In 2025, the liquidity ratio of NATASCHA PHARMA (156.16) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of NATASCHA PHARMA in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of NATASCHA PHARMA is estimated at
468 690 €
(range 318 055€ - 735 439€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
318k€468k€735k€
468 690 €Range: 318 055€ - 735 439€
NAF 5 année 2025
Valuation method used
Net Income Multiple
29 505 €
×
15.9x
=468 690 €
Range: 318 056€ - 735 440€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare NATASCHA PHARMA with other companies in the same sector:
The revenue of NATASCHA PHARMA is not publicly disclosed (confidential accounts filed with INPI).
Is NATASCHA PHARMA profitable?
Yes, NATASCHA PHARMA generated a net profit of 30 k€ in 2025.
Where is the headquarters of NATASCHA PHARMA ?
The headquarters of NATASCHA PHARMA is located in SAINT-MAUR-DES-FOSSES (94210), in the department Val-de-Marne.
Where to find the tax return of NATASCHA PHARMA ?
The tax return of NATASCHA PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does NATASCHA PHARMA operate?
NATASCHA PHARMA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart